The board of directors of Tianjin TEDA Biomedical Engineering Company Limited announced that, based on the information currently available, including but not limited to the consolidated results of the company and its subsidiaries, the Group is expected to incur a loss attributable to shareholders for the year ended December 31, 2018 as compared with the loss of RMB 21,283,684 for the year ended December 31,2017. The Group will incur a significant loss for the year ended December 31,2018. Such loss is mainly due to the fact that the quantitative EEG detection business was not developed as expected as a result of the changes in operating environment. Hence, it is expected to make an impairment provision of its substantial intangible assets during the year.